Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCSL Limited

CSL Limited

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
139.16 USD 0.00(0%)
Last update at 2026-11-03T21:00:00Z
VOLUME
500
Market Cap
58550.68M

Momentum Score

…

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
135.00
Low
139.16
High
52 Week Price Range
62.99
Low
144.46
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CSL Limited is a global biotechnology company producing plasma-derived therapies and influenza vaccines through CSL Behring and Seqirus. Long-term growth drivers include rising demand for immunoglobulins and specialty biologics, expanded plasma collection and demographic ageing, and investors may view its large-scale integrated manufacturing and market leadership in plasma products as supportive of stable cash flows.
Material risks include regulatory and manufacturing complexity, reliance on plasma supply, pricing and competitive pressures, currency exposure and execution risk from investments.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
139.16
Dividend Yield
2.39%
Revenue TTM
15797.00M
Revenue Per Share
32.77
Gross Profit TTM
8075.00M
Debt / Equity
0.74
ROE
-15.84%
Net Debt
9369.32M
ROCE
14.49%
Diluted EPS TTM
-5.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4172.45M 3724.00M 3375.00M 2663.00M 2779.60M
Minority interest 407.00M -134.00M -72.00M -50.00M -
Net income -2632.92M 3002.00M 2642.00M 2194.00M 2254.70M
Selling general administrative 2611.00M 1000.00M 856.00M 1086.00M 688.00M
Selling and marketing expenses - 1616.00M 1573.00M 1454.00M 960.70M
Gross profit 7646.59M 7951.00M 7561.00M 6708.00M 5663.50M
Reconciled depreciation 1041.00M 1017.00M 938.00M 831.00M 542.50M
Ebit 4094.86M 4117.00M 3795.00M 3071.00M 2922.40M
Ebitda 5157.62M 5134.00M 4733.00M 3902.00M 3464.90M
Depreciation and amortization 1062.76M 1017.00M 938.00M 831.00M 542.50M
Operating income 4094.86M 2959.00M 3812.00M 3071.00M 2922.40M
Other operating expenses 11931.34M 12471.00M 11926.00M 11072.00M 8177.00M
Interest expense 438.99M 454.88M 484.22M 408.00M 142.80M
Tax provision -1101.00M 588.00M 661.00M 419.00M 524.90M
Interest income 30.00M 38.00M 39.00M 38.00M 17.40M
Net interest income -405.00M -410.00M -437.00M -406.00M -160.60M
Income tax expense -1124.02M 588.00M 661.00M 419.00M 524.90M
Total revenue 16026.20M 15430.00M 14800.00M 13174.00M 10493.10M
Total operating expenses 3551.74M 4992.00M 4797.00M 4606.00M 3347.40M
Cost of revenue 8379.60M 7479.00M 7129.00M 6466.00M 4829.60M
Total other income expense net -8267.31M 765.00M -437.00M 136.00M 81.60M
Net income from continuing ops -2986.00M 3136.00M 2714.00M 2244.00M 2254.70M
Net income applicable to common shares - - - 2194.00M 2254.70M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 33596.95M 39404.00M 38022.00M 36234.00M 28346.00M
Intangible assets 4592.30M 8120.00M 8267.00M 8367.00M 1450.80M
Other current assets 338.51M 345.00M 506.00M 9.00M 4.20M
Total liab 17313.72M 17997.00M 18621.00M 18408.00M 13768.50M
Total stockholder equity 14775.43M 19335.00M 17363.00M 15786.00M 14577.50M
Other current liab 3368.08M 3203.00M 2963.33M 2733.00M 2022.40M
Common stock 4378.61M 574.00M 557.00M 517.00M 483.80M
Capital stock -120.00M 574.00M 557.00M 517.00M 483.80M
Retained earnings 13678.03M 17744.00M 16012.00M 14621.00M 13503.40M
Other liab - - - 2628.00M 1496.50M
Good will 6355.72M 8065.00M 8079.00M 8079.00M 1187.30M
Other assets - - - 1177.00M 938.60M
Cash 1510.79M 2157.00M 1657.00M 1548.00M 10436.40M
Total current liabilities 5346.19M 4815.00M 4950.00M 4608.00M 7108.20M
Current deferred revenue - - 3129.00M - -
Net debt 9369.32M 9341.00M 10526.00M 10679.00M -778.60M
Short term debt 1140.34M 804.00M 944.00M 1055.00M 4494.00M
Short long term debt 1003.00M 695.00M 848.00M 964.00M 4420.50M
Short long term debt total 10880.11M 11498.00M 12183.00M 12227.00M 9657.80M
Other stockholder equity -4498.43M - - 648.00M 0.00M
Property plant equipment - - - 9352.00M 8308.60M
Total current assets 11814.75M 11850.00M 10768.00M 9259.00M 16460.70M
Long term investments 154.00M 203.00M 163.00M 173.00M 402.90M
Net tangible assets - - - -660.00M 11939.40M
Net receivables 3348.11M 2882.00M 2641.00M 1905.00M 1483.20M
Long term debt 8380.00M 9141.00M 9671.00M 9564.00M 3862.50M
Inventory 6617.34M 6466.00M 5964.00M 5466.00M 4333.00M
Accounts payable 837.78M 808.00M 867.00M 820.00M 591.80M
Accumulated other comprehensive income 1217.22M 1017.00M 794.00M 648.00M 590.30M
Non currrent assets other 92.86M 278.00M 177.71M 204.00M 36.40M
Non current assets total 21782.20M 27554.00M 27254.00M 26975.00M 11885.30M
Capital lease obligations 1513.00M 1662.00M 1664.00M 1699.00M 1374.80M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments 4.00M -850.00M -1259.00M -11843.00M -387.70M
Change to liabilities - - - 197.00M 212.30M
Total cashflows from investing activities -1297.57M -850.00M -1259.00M -11843.00M -1636.10M
Net borrowings -470.00M -735.00M 41.00M 1661.00M 3723.70M
Total cash from financing activities -2887.12M -2241.00M -1284.00M 456.00M 7675.90M
Change to operating activities - - - 51.00M -102.70M
Net income -2632.92M 3002.00M 2687.61M 2194.00M 2254.70M
Change in cash -653.55M 514.00M 134.00M -8825.00M 8604.30M
Begin period cash flow 2164.34M 1643.00M 1509.00M 10334.00M 1730.10M
End period cash flow 1510.79M 2157.00M 1643.00M 1509.00M 10334.40M
Total cash from operating activities 3585.43M 3561.00M 2764.00M 2601.00M 2628.70M
Issuance of capital stock 30.00M 17.00M 40.00M 34.00M 4988.40M
Depreciation 1062.76M - 954.19M 831.00M 448.00M
Other cashflows from investing activities -3.06M -381.00M -410.00M - -0.70M
Dividends paid 1441.52M 1434.00M 1212.58M -1239.00M -1038.70M
Change to inventory -476.76M -637.65M -793.46M -907.00M -902.30M
Change to account receivables -573.75M -318.82M -779.22M 28.00M -44.60M
Sale purchase of stock -739.14M - - 2539.00M 4092.70M
Other cashflows from financing activities -257.27M -89.00M -152.42M 2459.00M 4042.60M
Change to netincome - - - 207.00M 668.80M
Capital expenditures 659.51M 1017.00M 1258.00M 1692.00M 1247.70M
Change in working capital -626.84M -878.29M -1587.00M - -
Stock based compensation - - 169.00M - -
Other non cash items 5782.42M 4439.29M 709.20M - -
Free cash flow 2925.92M 2544.00M 1506.00M -1692.00M -1247.70M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CMXHF
CSL Limited		 -
-%		 139.16 - 18.87 3.71 3.96 4.35 10.84
NVO
Novo Nordisk A/S		 1.99
4.95%		 42.18 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 18.28
3.44%		 549.04 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -41.91
4.31%		 931.45 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

655 Elizabeth Street, Melbourne, VIC, Australia, 3000

61 3 9389 1911

https://www.csl.com

29000

Name Title Year Born
Mr. Paul R. Perreault B.A. MD, CEO & Exec. Director 1957
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Chief Financial Officer 1965
Dr. Paul F. McKenzie Ph.D. COO & Exec. Director 1966
Mr. Mark Dehring Head of Investor Relations NA
Mr. Gregory Boss B.S., BS(Hons), J.D. Exec. VP of Legal & Group Gen. Counsel 1961
Christina Hickie Sr. Mang. of Communications NA
Ms. Elizabeth Walker B.A., M.S. Exec. VP & Chief HR Officer 1970
Dr. Karen Etchberger Exec. VP of Quality & Bus. Services 1958
Dr. Wilfried Freudenberg Department Head of Albumin & Immunoglobulins Production NA
Ms. Jemimah Brennan Head of Communications - Asia Pacific NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…